$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 2026年1月，《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南》2026版草案已将TY-9591列为EGFR突变伴脑转移患者一线推荐方案，提升临床认可度

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":531572676282000,"tweetId":"531572676282000","gmtCreate":1770797574241,"gmtModify":1770797576643,"author":{"id":4184381897673700,"idStr":"4184381897673700","authorId":4184381897673700,"authorIdStr":"4184381897673700","name":"曼曼在海南","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 2026年1月，《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南》2026版草案已将TY-9591列为EGFR突变伴脑转移患者一线推荐方案，提升临床认可度</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 2026年1月，《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南》2026版草案已将TY-9591列为EGFR突变伴脑转移患者一线推荐方案，提升临床认可度</p></body></html>","text":"$同源康医药-B(02410)$ 2026年1月，《中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南》2026版草案已将TY-9591列为EGFR突变伴脑转移患者一线推荐方案，提升临床认可度","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/531572676282000","repostId":0,"isVote":1,"tweetType":1,"viewCount":58,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":147,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}